Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Santen Pharmaceutical Co ( (JP:4536) ) has issued an update.
Santen Pharmaceutical Co., Ltd. announced the status of its share buyback, having repurchased 4,188,500 common shares for 6,971,424,200 yen between July 1 and July 31, 2025. This buyback is part of a broader plan approved by the Board of Directors to repurchase up to 19,800,000 shares, representing 5.8% of the total shares outstanding, with a maximum budget of 35 billion yen. The buyback aims to enhance shareholder value and optimize capital structure.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen1900.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen focuses on research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries.
Average Trading Volume: 1,265,764
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen570.4B
See more insights into 4536 stock on TipRanks’ Stock Analysis page.